BIOMARIN PHARMACEUTICAL INC Amortization of Intangible Assets
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Amortization of Intangible Assets of $73.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC amortization of intangible assets for the quarter ending 2026-06-30 was $73.49M, a 1416.55% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC amortization of intangible assets for the quarter ending 2026-03-31 was $4.48M, a 7.51% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC amortization of intangible assets for the quarter ending 2025-12-31 was $4.85M, a 49.79% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC amortization of intangible assets for the quarter ending 2025-09-30 was $4.85M, a 3.23% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC amortization of intangible assets for fiscal 2025 was $19.39M, a 55.18% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC amortization of intangible assets for fiscal 2024 was $43.26M, a 30.47% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC amortization of intangible assets for fiscal 2023 was $62.21M, a 7.41% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC amortization of intangible assets for fiscal 2022 was $67.19M.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $73.49M 10-Q · filed 2026-08-06 | $77.97M 10-Q · filed 2026-08-06 | $82.82M derived: sum of 3 quarters · filed 2026-08-06 | $87.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.48M 10-Q · filed 2026-05-05 | $9.33M derived: sum of 2 quarters · filed 2026-05-05 | $14.18M derived: sum of 3 quarters · filed 2026-05-05 | $19.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.69M derived: sum of 2 quarters · filed 2026-02-26 | $14.54M derived: sum of 3 quarters · filed 2026-08-06 | $19.39M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.85M 10-Q · filed 2025-10-28 | $9.69M derived: sum of 2 quarters · filed 2026-08-06 | $14.54M 10-Q · filed 2025-10-28 | $24.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.85M 10-Q · filed 2026-08-06 | $9.69M 10-Q · filed 2026-08-06 | $19.34M derived: sum of 3 quarters · filed 2026-08-06 | $24.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.85M 10-Q · filed 2026-05-05 | $14.50M derived: sum of 2 quarters · filed 2026-05-05 | $19.51M derived: sum of 3 quarters · filed 2026-05-05 | $33.81M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $9.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.66M derived: sum of 2 quarters · filed 2026-02-26 | $28.96M derived: sum of 3 quarters · filed 2026-02-26 | $43.26M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.01M 10-Q · filed 2025-10-28 | $19.31M derived: sum of 2 quarters · filed 2025-10-28 | $33.61M 10-Q · filed 2025-10-28 | $48.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $14.30M 10-Q · filed 2025-08-05 | $28.60M 10-Q · filed 2025-08-05 | $43.83M derived: sum of 3 quarters · filed 2026-02-26 | $59.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $14.30M 10-Q · filed 2025-05-02 | $29.53M derived: sum of 2 quarters · filed 2026-02-26 | $45.22M derived: sum of 3 quarters · filed 2026-02-26 | $60.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $15.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $30.92M derived: sum of 2 quarters · filed 2026-02-26 | $46.54M derived: sum of 3 quarters · filed 2026-02-26 | $62.21M 10-K · filed 2026-02-26 |
| 2023-09-30 | $15.68M 10-Q · filed 2024-10-31 | $31.30M derived: sum of 2 quarters · filed 2024-10-31 | $46.98M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $15.62M 10-Q · filed 2024-08-05 | $31.29M 10-Q · filed 2024-08-05 | ||
| 2023-03-31 | $15.67M 10-Q · filed 2024-04-26 | |||
| 2022-12-31 | $67.19M 10-K · filed 2025-02-24 | |||
| 2014-12-31 | $10.48M 10-K · filed 2015-03-02 | |||
| 2012-12-31 | $6.80M 10-K · filed 2013-02-26 | |||
| 2011-12-31 | $500.00K 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |